X4 Pharmaceuticals

X4 Pharmaceuticals Secures Positive EMA CHMP Opinion for Mavorixafor in WHIM Syndrome

FDA · WHIM Syndrome · 5 min

X4 Pharmaceuticals has achieved a significant milestone with a positive opinion from the EMA's CHMP for Mavorixafor, a treatment for WHIM Syndrome. This recommendation moves the company closer to European market entry and has notable implications for the rare disease landscape.